L-MIND was an open-label, multicenter, single-arm, Phase 2 study in adult patients with R/R DLBCL who were not eligible for or refused ASCT1,2
Efficacy was established based on best ORR (defined as the proportion of complete and partial responders), and DoR, as assessed by an Independent Review Committee using the International Working Group Response Criteria (Cheson 2007).1 See full study design here
High ORR reached, with a majority of responders achieving a complete response
1-year primary analysis in patients with R/R DLBCL (N=71) showed high ORR1*
Twice as many patients experienced a best response of CR.
Median time to response3
In the L-MIND study (N=71), the median time to response was 2.0 months3
Median time to CR: 10.9 months (n=25)
Median time to PR: 1.9 months (n=26)
The time-to-response analysis is exploratory in nature. These results should be interpreted with caution due to single-arm studies not adequately characterizing time-to-event endpoints, and the small sample size, which may lead to estimates that are unstable.
Median DoR in patients with R/R DLBCL1
Median duration of response1*†
Median DoR 21.7 months (range: 0, 24)
*Assessed by an Independent Review Committee.1
The cutoff date for the primary analysis was November 30, 2018, and occurred after the last patient enrolled had completed 12 months of follow-up.4